Literature DB >> 9796706

Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression.

R P Somerville1, Y Shoshan, C Eng, G Barnett, D Miller, J K Cowell.   

Abstract

The transition from low grade astrocytoma to glioblastoma multiforme is almost always accompanied by the loss of genetic markers from chromosome 10. Recently two genes, PTEN/MMAC1/TEP1 and DMBT, have been isolated from chromosome 10q. We have analysed these two genes for mutations in 21 primary glioblastomas. An exon by exon screen of the PTEN gene using SSCP failed to identify any mutations in this tumour series. In contrast, 38% of tumours showed intragenic homozygous deletions in the DMBT gene. The fact that the majority of gliomas do not carry mutations in either of these genes suggests that there may still be other genes on chromosome 10 which are important in the development of glioblastoma multiforme.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796706     DOI: 10.1038/sj.onc.1202066

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.

Authors:  H Sasaki; M C Zlatescu; R A Betensky; Y Ino; J G Cairncross; D N Louis
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Role of integrins in the assembly and function of hensin in intercalated cells.

Authors:  Soundarapandian Vijayakumar; Hediye Erdjument-Bromage; Paul Tempst; Qais Al-Awqati
Journal:  J Am Soc Nephrol       Date:  2008-03-12       Impact factor: 10.121

3.  Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.

Authors:  C Ebert; M von Haken; B Meyer-Puttlitz; O D Wiestler; G Reifenberger; T Pietsch; A von Deimling
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  The scavenger receptor, cysteine-rich domain-containing molecule gp-340 is differentially regulated in epithelial cell lines by phorbol ester.

Authors:  W Kang; O Nielsen; C Fenger; J Madsen; S Hansen; I Tornoe; P Eggleton; K B M Reid; U Holmskov
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

5.  PTEN mutations in malignant gliomas and their relation with meningeal gliomatosis.

Authors:  S Izumoto; T Ohnishi; H Kanemura; N Arita; M Maruno; T Moriuchi; S Suzuki; T Yoshimine
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

Review 6.  Genetics of brain neoplasms.

Authors:  J R Shapiro
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

7.  Global transcriptional response to carbonic anhydrase IX deficiency in the mouse stomach.

Authors:  Heini Kallio; Mika Hilvo; Alejandra Rodriguez; Eeva-Helena Lappalainen; Anna-Maria Lappalainen; Seppo Parkkila
Journal:  BMC Genomics       Date:  2010-06-23       Impact factor: 3.969

Review 8.  Deleted in malignant brain tumors-1 protein (DMBT1): a pattern recognition receptor with multiple binding sites.

Authors:  Antoon J M Ligtenberg; Niclas G Karlsson; Enno C I Veerman
Journal:  Int J Mol Sci       Date:  2010-12-17       Impact factor: 5.923

9.  A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3).

Authors:  Jens Madsen; Grith Lykke Sorensen; Ole Nielsen; Ida Tornøe; Lars Thim; Claus Fenger; Jan Mollenhauer; Uffe Holmskov
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

Review 10.  CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.

Authors:  Christos Liaskos; Eirini I Rigopoulou; Timoklia Orfanidou; Dimitrios P Bogdanos; Christos N Papandreou
Journal:  Clin Dev Immunol       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.